Data from the Phase 1 clinical trial of novel KCNK13 inhibitor showed good CNS exposure and was generally ...

Panelists discuss how organizations must create system-wide cultural changes through staff training, appropriate clinical environments, evidence-based treatment access, and incentive structures that ...